When prepared by FDA-registered compounding pharmacies, both have equivalent safety and effectiveness profiles
For topical applications Some users reconstitute GHK-Cu for topical rather than injectable use
Proper management of blood sugar levels is crucial for reducing the risk
Phase 2 results at 48 weeks (Jastreboff et al., NEJM 2023): Phase 3 TRIUMPH-4 at 68 weeks (Lilly Press Release, Dec 2025): The 12 mg dose produced 28.7% body weight loss, an average of 71.2 lbs from a 248.5 lb baseline
Sugiyama A, Ohta T, Obata M, Takahashi K, Seino M, Nagase S
Indication-specific labeling reinforces this divergence